Latest amphotericin B Stories

Analysis will help development of new treatments to protect vulnerable patients undergoing chemotherapy or suffering from HIV Neutron scattering experiments have provided new insights into the origin of the side effects of an antifungal drug prescribed all over the world. The analysis conducted by scientists at King's College London and the Institut Laue-Langevin in Grenoble, and published in Scientific Reports, follows 40 years of debate and could help drug developers reduce these harmful...

The most cost-effective treatment for cryptococcal meningitis (a serious infection of the brain membranes, usually in people with AIDS or other immune system deficiencies) is different to that currently recommended by the World Health Organization (WHO), warranting a review of policy, according to the findings of a study published in this week's PLOS Medicine. Researchers from Makerere University in Kampala, Uganda, and from the University of Minnesota in the US found that a short (7-day)...

With one simple experiment, University of Illinois chemists have debunked a widely held misconception about an often-prescribed drug. Led by chemistry professor and Howard Hughes Medical Institute early career scientist Martin Burke, the researchers demonstrated that the top drug for treating systemic fungal infections works by simply binding to a lipid molecule essential to yeast's physiology, a finding that could change the direction of drug development endeavors and could lead to better...

A new formulation of Amphotericin B (AmB) developed by University of British Columbia researchers has been shown to be stable in tropical climates and effective in treating Visceral Leishmaniasis (VL) in mouse models.VL is a blood-born parasitic disease that afflicts 12 million people worldwide, mainly in developing countries and tropical regions. According to the World Health Organization (WHO), 1.5 million new cases of the disease are reported every year, and 60,000 people die from it.AmB,...

By Thakur, C P Paromomycin, an aminoglycoside, is known to cause several side effects like nephrotoxicity and ototoxicity like other aminoglycosides but tetany has not been reported. Three cases of tetany were detected in the patients of kala-azar treated with paromomycin. They were promptly treated with intravenous 10 per cent calcium gluconate and tetany was relieved immediately and treatment with paromomycin continued with oral calcium supplement. After completion of 21 days treatment...

BioDelivery Sciences International has initiated its first Phase I clinical study assessing the safety, tolerability and pharmacokinetics of Bioral amphotericin B. This study is said to represent a significant step forward in the evaluation of BDSI's second drug delivery platform, known as Bioral. BioDelivery Sciences International's (BDSI) Bioral drug delivery system appears to protect certain drugs from degradation in the gastrointestinal tract and facilitates their oral absorption through...

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) has initiated its first Phase I clinical study assessing the safety, tolerability and pharmacokinetics of Bioral(R) Amphotericin B. This study represents a significant step forward in the evaluation of BDSI's second drug delivery platform, known as Bioral(R). The Bioral(R) drug delivery system appears to protect certain drugs from degradation in the gastrointestinal tract and facilitates their oral absorption through a novel process...

By Chen, Hua Suda, Katie J; Turpin, Robin S; Pai, Manjunath P; Et al Key words: Candidiasis - Cost-effectiveness analysis - Fluconazole - Pharmacoeconomics ABSTRACT Background: High-dose fluconazole is an alternative for patients with candidemia caused by Candida glabrata or other Candida species with decreased fluconazole susceptibility. However, empiric high- dose fluconazole is not currently recommended and may result in higher drug costs and toxicity. Objective: To determine the...